Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
12/04/17
Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 4, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to microbiome therapeutic candidate SER-287 for the treatment of Ulcerative Colitis (UC) in pediatric patients. Orphan Drug Designation provides incentives designed to advance drug development for rare diseases or conditions that affect fewer than ... 
11/14/17
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB), The University of Texas MD Anderson Cancer Center (MD Anderson), and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced a collaboration to evaluate the potential of Seres’ microbiome therapies to improve the outcomes of cancer patients treated with currently-available immunotherapy. This press release features multimedi... 
11/08/17
Seres Therapeutics to Participate in Three Upcoming November Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced that it will participate in each of the following upcoming healthcare conferences: Stifel 2017 Healthcare Conference: A corporate overview will be presented on Tuesday, November 14 at 5:00 p.m. ET in New York, NY. 29th Annual Piper Jaffray Healthcare Conference: A corporate overview will be presented on ... 
EventsMore
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$9.93
 - 0.15 (1.49%)
12/14/17 11:28 a.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.